PNH
Advertising Networks · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1985 Hymus Blvd, Dorval, Quebec, H9P 1J8...Phone Number
(888) 808-3279Website
www.pnh.caRevenue
$22.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About PNH
PNH Solutions specializes in innovative event marketing, custom displays, and fabric printing across Canada. They provide personalized marketing solutions to help brands engage with their audience and build lasting relationships. Their offerings include a wide range of products such as banners, trade show displays, and custom event tents. With a commitment to quality and customer service, PNH Solutions serves both emerging and established brands looking to create impactful brand experiences.Explore more
PNH Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PNH your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at PNH
Product Launch: Get notified when PNH launches new products
PNH, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once PNH has new funding data
Click to see if PNH had a recent Job posting/layoffs
Earning: See what the market has to say on PNH recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if PNH is spiking on competitors!
Check if PNH has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at PNH
Find 3 more new buyers
Compare Similar Companies to PNH
Compare insights from companies similar to PNH, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PNH is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
PNH is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about PNH.
PNH Tech Stack
A closer look at the technologies used by PNH
See more technologies
PNH News & Media
Empaveli is the first treatment for PNH that binds to the complement protein C3.
SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and OrphanDC announced on July 25th that ANVISA, the National Health Surveillance Agency, approved, on July 25th, 2023, the drug EMPAVELI® (pegcetacoplan, indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)). Empaveli is the first treatment for PNH that binds to the complement protein C3. PNH is a rare, chronic, and life-threatening blood disease in which uncontrolled complement activation leads to the destruction of red bNew data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress
Swedish Orphan Biovitrum AB (publ) (Sobi (https://www.sobi.com/en/media)®) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies that reinforce the robust efficacy and safety profile of Aspaveli®/Empaveli® (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with Aspaveli/Empaveli resulApellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
WALTHAM, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the United States and European Union,EHA25Virtual: Pegcetacoplan, a Novel C3 Complement Inhibitor - Beginning of a New Era in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- PNH is a rare but severe and usually life-long blood disease in which the blood cells are fragile and easily destroyed by a part of the patient's own immune system, called complement. In PNH, this results in fatigue and severe anaemia,...
Read more news
Top Advertising Networks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding PNH
Sign Up For FreeTo access detailed company insights
PNH Solutions specializes in innovative event marketing, custom displays, and fabric printing across Canada. They provide personalized marketing solutions to help brands engage with their audience and build lasting relationships. Their offerings include a wide range of products such as banners, trade show displays, and custom event tents. With a co... Read More
